治疗耐药高血压:什么是最好的药理选择?
Joseph M Walter1, Andrew Giaquinto
1At the Ernest Mario School of Pharmacy at Rutgers University in Piscataway, NJ, Joseph M. Walter and Andrew Giaquinto are clinical assistant professors. The authors have disclosed no potential conflicts of interest, financial or otherwise.
JAAPA : official journal of the American Academy of Physician Assistants
|September 25, 2025
概括
耐性高血压 (RH) 是三种一线药物无法控制的高血压 (BP). 本文回顾了基于证据的二线药物选择,用于在初始治疗失败时管理RH.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 耐性高血压 (RH) 影响患者的血压 (BP) 仍然不受控制,尽管最佳的第一线治疗.
- 定义RH涉及BP超出目标尽管有三个一线药理学类或需要四种或更多的药物.
- 在考虑二线药理选择之前,应解决二次原因和非药理策略.
研究的目的:
- 讨论基于证据的抗性高血压的二线药物选择.
- 为指导临床医生在初始疗法不足后选择适合RH的药理疗法.
主要方法:
- 对抗性高血压的基于证据的药理疗法的文献综述.
- 讨论二线药物类别及其在RH管理中的有效性.
主要成果:
- 确定RH的关键二线药物选择.
- 支持使用这些剂来实现BP控制的证据摘要.
结论:
- 适当选择二线药物对于管理耐性高血压至关重要.
- 基于证据的策略可以帮助临床医生优化治疗不受控制的高血压患者.
相关概念视频
Hypertension IV: Drug Therapy and Lifestyle Modifications
624
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
624
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
442
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
442
Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K


